Determine whether MRI activity @ months after treatment initiation in the Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study ( CHAMPS ) predicted progression to clinically definite multiple sclerosis ( CDMS ) over the subsequent @ months in intramuscular interferon beta-@a ( IM IFN-@a ) - treated patients vs placebo-treated patients .